These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34250421)

  • 1. Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion.
    Greenberg SE; Hunt TC; Ambrose JP; Lowrance WT; Dechet CB; O'Neil BB; Tward JD
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
    Giri VN; Hegarty SE; Hyatt C; O'Leary E; Garcia J; Knudsen KE; Kelly WK; Gomella LG
    Prostate; 2019 Mar; 79(4):333-339. PubMed ID: 30450585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.
    Nicolosi P; Ledet E; Yang S; Michalski S; Freschi B; O'Leary E; Esplin ED; Nussbaum RL; Sartor O
    JAMA Oncol; 2019 Apr; 5(4):523-528. PubMed ID: 30730552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
    Theobald KA; Susswein LR; Marshall ML; Roberts ME; Mester JL; Speyer D; Williams RNW; Knapke SC; Solomon SR; Murphy PD; Klein RT; Hruska KS; Solomon BD
    Ann Surg Oncol; 2018 Nov; 25(12):3556-3562. PubMed ID: 30167906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients.
    Isiklar AD; Aliyeva L; Yesilyurt A; Soyder A; Basaran G
    Breast Cancer Res Treat; 2023 Nov; 202(2):297-304. PubMed ID: 37615792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
    Ledet EM; Burgess EF; Sokolova AO; Jaeger EB; Hatton W; Moses M; Miller P; Cotogno P; Layton J; Barata P; Lewis BE; Nakazawa M; Zhu J; Dellinger B; Elrefai S; Nafissi NN; Egan JB; Shore N; McKay RR; Bryce AH; Cheng HH; Antonarakis ES; Sartor O
    Prostate; 2021 May; 81(7):433-439. PubMed ID: 33792945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
    Sabol RA; Ledet EM; Jaeger E; Hatton W; Moses M; Lankford A; Zaheria A; Barata P; Layton JL; Lewis BE; Sartor O
    Prostate; 2021 May; 81(7):427-432. PubMed ID: 33760238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.
    Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
    Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial outcomes and insights from a novel high-risk prostate cancer screening clinic.
    Harper JB; Greenberg SE; Hunt TC; Cooney KA; O'Neil BB
    Prostate; 2023 Feb; 83(2):151-157. PubMed ID: 36207779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
    Isaacsson Velho P; Silberstein JL; Markowski MC; Luo J; Lotan TL; Isaacs WB; Antonarakis ES
    Prostate; 2018 Apr; 78(5):401-407. PubMed ID: 29368341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethnic disparities among men with prostate cancer undergoing germline testing.
    Kwon DH; Borno HT; Cheng HH; Zhou AY; Small EJ
    Urol Oncol; 2020 Mar; 38(3):80.e1-80.e7. PubMed ID: 31630993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years.
    Desai NV; Yadav S; Batalini F; Couch FJ; Tung NM
    Cancer; 2021 Mar; 127(6):828-833. PubMed ID: 33146899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer.
    Gheybi K; Jiang J; Mutambirwa SBA; Soh PXY; Kote-Jarai Z; Jaratlerdsiri W; Eeles RA; Bornman MSR; Hayes VM
    J Natl Compr Canc Netw; 2023 Mar; 21(3):289-296.e3. PubMed ID: 36898365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline DNA Repair Genes Pathogenic Variants Among Mexican Patients With Prostate Cancer.
    Chávarri-Guerra Y; Bourlon MT; Rodríguez-Olivares JL; Orozco L; Bazua D; Rodríguez-Faure A; Alcalde-Castro MJ; Castro E; Castillo D; Herzog J; Weitzel J
    Clin Genitourin Cancer; 2023 Oct; 21(5):569-573. PubMed ID: 37380563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
    Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
    J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Germline Variants in Patients With Localized and Metastatic Prostate Cancer Through Guideline-Based Testing.
    Abusamra SM; Solorzano MA; Quarles J; Luke M; Patel M; Vince R; Jiang R; Volin J; Jacobs MF; Kaffenberger SD; Salami SS; Palmbos P; Caram MEV; Hollenbeck BK; Palapattu GS; Merajver SD; Stoffel EM; Hafron J; Morgan TM; Reichert ZR
    Urol Pract; 2025 Jan; 12(1):63-72. PubMed ID: 39383006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial.
    Shore N; Gazi M; Pieczonka C; Heron S; Modh R; Cahn D; Belkoff LH; Berger A; Mazzarella B; Veys J; Idom C; Morris D; Jayram G; Engelman A; Bukkapatnam R; Dato P; Bevan-Thomas R; Cornell R; Wise DR; Hardwick MK; Hernandez RD; Rojahn S; Layman P; Hatchell KE; Heald B; Nussbaum RL; Nielsen SM; Esplin ED
    Eur Urol Oncol; 2023 Oct; 6(5):477-483. PubMed ID: 37574391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
    Yadav S; Hu C; Hart SN; Boddicker N; Polley EC; Na J; Gnanaolivu R; Lee KY; Lindstrom T; Armasu S; Fitz-Gibbon P; Ghosh K; Stan DL; Pruthi S; Neal L; Sandhu N; Rhodes DJ; Klassen C; Peethambaram PP; Haddad TC; Olson JE; Hoskin TL; Goetz MP; Domchek SM; Boughey JC; Ruddy KJ; Couch FJ
    J Clin Oncol; 2020 May; 38(13):1409-1418. PubMed ID: 32125938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.
    Lertwilaiwittaya P; Roothumnong E; Nakthong P; Dungort P; Meesamarnpong C; Tansa-Nga W; Pongsuktavorn K; Wiboonthanasarn S; Tititumjariya W; Thongnoppakhun W; Chanprasert S; Limwongse C; Pithukpakorn M
    Breast Cancer Res Treat; 2021 Jul; 188(1):237-248. PubMed ID: 33649982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
    Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
    Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.